HERA: Key Design Elements, Results and Future Plans
Hera: Key Design Elements, Results and Future Plans
First Results of the Hera Trial
Accrual: 5090 Women 478 centers from 39 countries (2002-2005)
Hera Trial Design
Key Differences
Key Inclusion Criteria
Endpoints and Analysis Plan
Hera Flow Chart
Patient/Tumor Characteristics
Patient/Tumor Characteristics
Patient/Tumor Characteristics
Adjuvant Endocrine Therapy
Overview of Adverse Events
Safety Analysis Polulation Cardiotoxicity
Disease-Free Survival
Disease-Free Survival Type of First Event
DFS Benefit in Subgroups HR: 1 year trastuzumab vs observation
Secondary Efficacy Endpoints Intent-to-treat Analysis
Conclusions: 1
Conclusions: 2
Conclusions: Overall
Follow-up: 1
ER-Negative and ER Positive; Study 8541
ER-Negative and ER Positive; Study9741
Hera Trial Design
Follow-up: 2
Brian Leyland-Jones, MD, PhD